Magnet Biomedicine的动态

Curious about how strategic structural modifications can shape ADME properties and inspire your next design iteration? The recording of Lewis Pennington's Flash Talk on the "Strategic Use of the Necessary Nitrogen Atom for Property-based Drug Design" is now live on our YouTube channel! In this Flash Talk, Lew explores the evolution of property-based drug design, highlighting foundational concepts in holistic drug design. He discusses selected case studies that showcase the profound impact of the "necessary nitrogen atom" on ADME properties—including solubility, permeability, chemical and metabolic stability, oral bioavailability, and even preclinical toxicity assessments. Watch his presentation and share it with your team here: https://lnkd.in/guZpHvYj

We are steadfast in our pursuit of valuable collaborations that enhance our existing portfolio and benefit researchers. Our commitment to advancing #nephrologyresearch has led to our latest partnership with Cell4Pharma. As a fellow contract research organization, Cell4Pharma provides cutting-edge nephrology screening assays, offering critical insights into the ADME(T) properties of new compounds. This collaboration, combined with our nephrology platform and team of experts, enables us to offer more comprehensive analysis during your in vitro studies. Below we have included an excerpt from the latest edition of Biotech News and Life Sciences published by Hyphen Projects detailing the collaboration. #PreclinicalCRO #EuropeanCRO #Nephrotoxicity #ADPKD #invitrostudies

Orbit’s functional screening platform is transforming peptide discovery by unlocking the potential of orphaned GPCRs. Our innovative approach identifies functional peptides that drive therapeutic breakthroughs. Discover how our platform is advancing drug discovery and accelerating therapeutic development ??. Attending the #BiotechShowcase or #JPM2025 next week? Connect with our CEO, Neil Butt, to learn how Orbit can help advance your therapeutic pipeline!

"Dock Orforglipron to P43220" Over the past few months, I’ve been exploring the complexities of the GLP-1 industry and, more recently, how GLP-1 drugs interact with the GLP-1R receptor. Yesterday, I attended an insightful session hosted by 310.ai, a molecular programming model that enables text-to-protein generation. In less than 30 minutes, Kooshiar Azimian, co-founder of 310.ai, demonstrated how to use their platform to generate molecules. Today, I experimented with docking Orforglipron—the oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly and Company—to P43220, the Uniprot ID for the GLP-1 receptor. The advancements in AI-driven drug discovery are truly inspiring. Thank you, Kooshiar Azimian, for hosting yesterday’s session. If you’re ever on the East Coast, coffee is on me! To view the molecules I generated, check out this link: https://lnkd.in/eaq32TRK To view the slides from yesterday, click on this link: https://lnkd.in/ee2JUUyR

The latest sponsored Drug Discovery World Sitting Down With vodcast features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory. He discusses alternatives to non-human primates, the key benefits of this, and what impact will they have on the future of drug development. Moreover, he answers questions on the key breakthroughs in recent years in this field and how have these impacted future success, as well as challenges in the clinic that must be overcome to ensure this success is achieved. #DrugDiscovery #DrugDevelopment

? #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials.? ?? Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. ?? The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain. ?? Are you curious about AVITHRAPID's WP7 (Fraunhofer-Gesellschaft zur F?rderung der angewandten Forschung) ? ?? Take a look below! ?? ?? Work Packages

?? Are you curious about AVITHRAPID's WP4 (Dompé farmaceutici SpA) ? ?? Take a look below! ?? ?? Work Packages ? #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials. ?? Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. ?? The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. ?? To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain.

Today, we want to highlight our success in solving the high-resolution CryoEM structure of ABCC4! ?? This achievement was made possible through the collaboration between our Membrane Protein and CryoEM teams. Their combined expertise and dedication were instrumental in unraveling the structure of ABCC4. This internal project establishes a strong foundation for advancing the understanding of ABCC4’s function and mechanisms and for developing targeted drug therapies ?? . We’re proud to contribute to the growing understanding of membrane proteins and their implications in drug discovery. Stay tuned for more exciting advancements from our team!

I’m thrilled to share our latest work published in ACS Omega, where we introduce a new high-throughput screening method for identifying peptide activators of G-Protein-Coupled Receptors (GPCRs). This innovative approach could revolutionize drug discovery by enabling rapid identification of peptide-based compounds that modulate GPCRs, a critical class of targets in medicine. https://lnkd.in/gsWsff73

?? Are you curious about AVITHRAPID's WP6 (Chelonia Applied Science SA) ? ?? Take a look below! ?? ?? Work Packages ? #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials. ?? Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. ?? The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain.